ArticleClinical and experimental pediatrics2026
Current review of pediatric Fas-associated death domain protein deficiency: expanding clinical and therapeutic perspectives.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fas-associated death domain protein (FADD) deficiency is a rare inborn error of immunity characterized by dysregulated T-cell proliferation. The clinical spectrum and management of FADD deficiency in children remain incompletely described. This review aimed to synthesize patient-level observational evidence on clinical manifestations, immunological and genetic findings, and treatment outcomes of pediatric patients with FADD deficiency. A literature search was conducted of PubMed, the Cochrane Library, and Scopus from database inception to July 2, 2026, and reference lists of eligible articles were reviewed. Inclusion criterion was articles on human clinical studies of patients with FADD gene mutation. Eligibility screening and data extraction were performed independently. Ten articles describing 18 patients were included. The reported ancestries included South Asian (n=9), European (n=6), and East/Central Asian (n=1). Parental consanguinity was reported in 10 of 12 patients (83.3%). Median age at onset was 0.8 years. Major presentations were fever-related encephalopathy, lymphoproliferation, and invasive pneumococcal disease. Common features included liver dysfunction, seizures, and functional hyposplenism. Regarding immunophenotyping, double-negative T cells were elevated in 9 of 10 patients (90%). Elevated soluble FAS ligand and interleukin-10 levels and defective lymphocyte apoptosis were observed in all tested patients; most patients had elevated vitamin B12 levels. The most common pathogenic variant was c.350G>A, followed by c.315T>G. Six patients died (33%) at a median age of 0.8 years. Mortality was high among patients with invasive pneumococcal disease; no deaths were reported among those with a lymphoproliferative phenotype or among the 2 hematopoietic stem cell transplantation recipients. FADD deficiency ranges from early-onset fever-related encephalopathy and fulminant sepsis to lymphoproliferative phenotypes. This review emphasizes the importance of recognizing FADD deficiency in children presenting with recurrent febrile encephalopathy, liver dysfunction, and a history of consanguinity and highlights prompt genetic evaluation and hematopoietic stem cell transplantation as potential curative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.